Merck (MRK), AstraZeneca (AZN) Report Update on Phase 3 GY004 for Cediranib & LYNPARZA (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. KRG
2. ALAR
3. CCH:LN
4. META
5. CCHGY
6. PRY:IM
7. PRYMY
8. SPY
9. OMV:AV
10. TEX

Go back to Merck (MRK), AstraZeneca (AZN) Report Update on Phase 3 GY004 for Cediranib & LYNPARZA (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer

Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer

March 12, 2020 3:00 AM EDT

The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival vs. Platinum-Based Chemotherapy

KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced high-level results from the Phase 3 GY004 trial, led by NRG Oncology and sponsored by the U.S. National Cancer Institute (NCI), that examined primarily the efficacy and safety of investigational medicine cediranib in combination with LYNPARZA versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. Ovarian cancer is the eighth... More